argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-08-10 07:28 |
argenx to Present at Wedbush PacGrow Healthcare Conference
|
English | 10.7 KB | ||
| 2016-06-30 07:38 |
argenx announces initial results from Phase 1 multiple ascending dose (MAD) stu…
|
English | 103.4 KB | ||
| 2016-06-03 08:03 |
argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-1…
|
English | 90.3 KB | ||
| 2016-06-03 07:32 |
argenx successfully closes €30 million private placement
|
English | 152.8 KB | ||
| 2016-06-01 07:41 |
argenx announces private placement of 2,703,000 new shares for an aggregate amo…
|
English | 124.3 KB | ||
| 2016-05-11 07:27 |
argenx Reports First Quarter 2016 Financial Results and Provides Business Update
|
English | 44.6 KB | ||
| 2016-04-29 09:23 |
argenx announces results of Annual General Meeting 2016
|
English | 89.8 KB | ||
| 2016-04-21 07:49 |
argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology
|
English | 103.3 KB | ||
| 2016-03-17 08:17 |
argenx announces Annual General Meeting of Shareholders 28 April 2016
|
English | 23.9 KB | ||
| 2016-03-16 17:19 | English | 4.1 MB | |||
| 2016-03-11 07:17 |
argenx reports fourth quarter business update and full year 2015 financial resu…
|
English | 83.1 KB | ||
| 2016-03-03 07:16 |
argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Upda…
|
English | 116.0 KB | ||
| 2016-02-26 08:20 |
argenx: Home Member State Selection
|
English | 86.6 KB | ||
| 2016-02-18 08:31 |
argenx opens clinical trial sites in South Korea for ARGX-111 program
|
English | 12.6 KB | ||
| 2016-02-05 08:19 |
argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conferen…
|
English | 34.1 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
